GDC-0349

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H32N6O3
Molecular Weight	452.5493
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCNC(=O)NC1=CC=C(C=C1)C2=NC(N3CCOC[C@@H]3C)=C4CCN(CC4=N2)C5COC5

InChI

InChIKey=RGJOJUGRHPQXGF-INIZCTEOSA-N

InChI=1S/C24H32N6O3/c1-3-25-24(31)26-18-6-4-17(5-7-18)22-27-21-12-29(19-14-33-15-19)9-8-20(21)23(28-22)30-10-11-32-13-16(30)2/h4-7,16,19H,3,8-15H2,1-2H3,(H2,25,26,31)/t16-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H32N6O3
Molecular Weight	452.5493
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900569

GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serine/threonine-protein kinase mTOR 35 Target ID: CHEMBL2842 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900569	Inhibitor 8504		3.8 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cancer 609 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24900569	Primary		Phase I 438	Unknown Approved Use Unknown
Non Hodgkin's lymphoma 1 Sources: https://clinicaltrials.gov/ct2/show/record/NCT01356173	Primary		Phase I 438	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
			inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
mTOR 1

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
mTOR 1	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027466/	strong [Ki 0.0038 uM]

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027466/

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P008TX0	https://www.1pchem.com/search?query=1P008TX0
AK Scientific	2427AH	https://aksci.com/item_detail.php?cat=2427AH
Angene	AGN-PC-0WCMRU	http://www.angenechemical.com/productshow/AGN-PC-0WCMRU.html
AOBIOUS INC	AOB87107	http://aobious.com/aobious/search?search_query=AOB87107
ApexBio Technology	A1642	https://www.apexbt.com/catalogsearch/result/?q=A1642
BLD Pharm	BD556704	http://www.bldpharm.com/search/Search.html?keyword=BD556704
BOC Sciences	1207360-89-1	http://www.bocsci.com/description.asp?cas=1207360-89-1
ChemShuttle	109849	https://www.chemshuttle.com/catalogsearch/result/?q=109849
eMolecules	275092337	https://orderbb.emolecules.com/search/#?query=275092337
eMolecules	300752920	https://orderbb.emolecules.com/search/#?query=300752920
eMolecules	44811454	https://orderbb.emolecules.com/search/#?query=44811454
eNovation Chemicals	K31313	https://www.enovationchem.com/Products.asp?SEARCHTEXT=K31313&searchbtn.x=0&searchbtn.y=0
Excenen	EX-A2248	http://www.excenen.com/searchresultlist.php?id=EX-A2248
Matrix Scientific	132331	http://www.matrixscientific.com/132331.html
mcule	MCULE-3007941471	https://mcule.com/MCULE-3007941471/
mcule	MCULE-6996999827	https://mcule.com/MCULE-6996999827/
MedChem Express	HY-15248	https://www.medchemexpress.com/search.html?q=HY-15248&ft=&fa=&fp=
Molnova	M17193	https://www.molnova.com/en/serch-list.html?keywords=M17193
MolPort	MolPort-028-720-439	https://www.molport.com/shop/molecule-link/MolPort-028-720-439
MuseChem	I000774	https://www.musechem.com/product/I000774.html
Selleck Chemicals	S8040	http://www.selleckchem.com/search.html?searchDTO.searchParam=S8040
ShangHai Biochempartner	BCP000741	http://www.biochempartner.com/search_BCP000741
ShangHai Biochempartner	BCP06869	http://www.biochempartner.com/search_BCP06869
TargetMol	T6510	https://www.targetmol.com/search?keyword=T6510
Toronto Research Chemicals	E926310	https://www.trc-canada.com/product-detail/?CatNum=E926310
Toronto Research Chemicals	H942567	https://www.trc-canada.com/product-detail/?CatNum=H942567

PubMed

Title	Date	PubMed
Autophagy induction contributes to GDC-0349 resistance in head and neck squamous cell carcinoma (HNSCC) cells.	2016-08-19	27291151
Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).	2013-04-11	23473235
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.	2013-01-10	24900569

Patents

Sample Use Guides

In Vivo Use Guide

oral GDC-0349 (10-160 mg/kg) demonstrates dose-dependent efficacy in mouse xenograft cancer models.

Route of Administration: Oral

In Vitro Use Guide

GDC-0349 demonstrates antiproliferative activity in PC3 cells at 270 nM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:54:17 GMT 2025` Edited by `admin` on `Mon Mar 31 20:54:17 GMT 2025`
Record UNII	579255I6O9
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GDC-0349

Preferred Name

English

Code System Code Type Description

DRUG BANK

DB13072